In HFmrEF or HFrEF, digitalis glycosides reduce a composite of CV death or worsening HF event vs. placebo at a median 36 to 37 mo

Dmitry Abramov, Harriette Van Spall, Unknown

Open source

DOI
10.7326/annals-26-03020-jc
Published
2026-09
Container
Annals of Internal Medicine
Publisher
American College of Physicians
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.7326/annals-26-03020-jc,
  title = {In HFmrEF or HFrEF, digitalis glycosides reduce a composite of CV death or worsening HF event vs. placebo at a median 36 to 37 mo},
  author = {Dmitry Abramov and Harriette Van Spall and Unknown},
  year = {2026},
  journal = {Annals of Internal Medicine},
  doi = {10.7326/annals-26-03020-jc},
  url = {https://doi.org/10.7326/annals-26-03020-jc}
}

RIS

TY  - JOUR
TI  - In HFmrEF or HFrEF, digitalis glycosides reduce a composite of CV death or worsening HF event vs. placebo at a median 36 to 37 mo
AU  - Dmitry Abramov
AU  - Harriette Van Spall
AU  - Unknown
PY  - 2026
JO  - Annals of Internal Medicine
DO  - 10.7326/annals-26-03020-jc
UR  - https://doi.org/10.7326/annals-26-03020-jc
ER  - 

APA

Abramov, D., Spall, H. V., & Unknown (2026). In HFmrEF or HFrEF, digitalis glycosides reduce a composite of CV death or worsening HF event vs. placebo at a median 36 to 37 mo. Annals of Internal Medicine. https://doi.org/10.7326/annals-26-03020-jc

Source records